Neomatrix SRL

Neomatrix is a biotechnology company developing next-generation personalised cancer immunotherapies based on nucleic acid technologies. Founded in 2020 as a spin-off from Takis Biotech, the company focuses on designing therapies that stimulate the immune system to recognize tumour-specific mutations.

Its lead program, Neo-Lin, is a personalised neoantigen cancer vaccine based on synthetic linear DNA (hpDNA) delivered by electroporation. The platform enables rapid production of patient-specific vaccines through a streamlined workflow—from tumour sequencing to vaccine administration—within approximately six weeks.

In parallel, Neomatrix is developing RNA-based immunotherapy approaches using lipid nanoparticle (LNP) technologies, including heterologous strategies combining DNA priming and mRNA-LNP boosting for cancers such as triple-negative breast cancer.

Through these platforms, Neomatrix aims to advance scalable and effective personalised cancer vaccines for precision oncology.